Tag: Major

Allergy and Asthma Group Practice Adopts Aerocrine’s FENO Testing, Providing Personalized Asthma Management Technology

SOLNA, Sweden – 12 August 2011 – Aerocrine AB today announced that Allergy & Asthma Specialists, P.C. has adopted Aerocrine’s FENO technology for airway inflammation measurement as part of its clinical standardization on a system-wide basis. Allergy & Asthma Specialists, P.C. is the largest group practice in the Philadelphia region specializing in allergic disease, asthma and immunology. Allergists use FENO to diagnose eosinophilic airway inflammation in patients with non-specific respiratory symptoms, to predict patient response to corticosteroid therapy, as well as to optimize dosing and assess adherence to anti-inflammatory therapy.

Allergy & Asthma Specialists, P.C. has eight locations in Philadelphia and surrounding suburbs. “We pride ourselves at providing our patients with the most up to date and comprehensive care,” said Dr. Robert Anolik, President of Allergy & Asthma Specialists, P.C. “Measurement of exhaled nitric oxide will enable us to provide optimal asthma management to our patients.”

“We are delighted to have this prestigious group of Allergy and Asthma Specialists on board with FENO testing, providing personalized asthma management”, said Kathy Hodgdon, Director of Sales & Marketing with Aerocrine. “In less than two minutes, this simple and inexpensive test makes it possible for physicians to better help patients living with asthma with appropriate therapy and disease control based on the patients’ individual needs.”

Asthma is a chronic inflammatory disease of the airways characterized by symptoms including wheezing and difficulty in breathing. The disease affects more than 300 million people around the world, of whom a significant number are children. Aerocrine’s founders made the original discovery that the levels of nitric oxide in exhaled breath, FENO, is elevated in patients with asthma. This has enabled a quick, effective and proactive method to measure the underlying inflammation in asthma, rather than being limited to reactively monitor its negative consequences in the form of symptoms and reduced lung function. The method has significant value in connection with diagnosis and choice of appropriate medication, as well as for the continuous management of asthma which is aimed at controlling the airway inflammation. Today, more than four million patient tests have been performed around the world using Aerocrine’s NIOX products.

For more information, contact:

Kathy Hodgdon, Director of Sales & Marketing, Aerocrine, Inc., telephone (314) 566-8546

Chip Neff, President, Aerocrine, Inc., telephone (919) 696-4267
Paul de Potocki, CEO, telephone: +46 8 629 07 80

For more information about Allergy & Asthma Specialists, please visit www.allergyandasthmawellness.com

About Aerocrine Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007. Aerocrine discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 a.m. on August the 12th 2011.